Capecitabine - Roche
Alternative Names: Capecitabine RDT; R340; RG 340; RO 091978; Ro09-1978; XelodaLatest Information Update: 05 Nov 2023
At a glance
- Originator Roche
- Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Ludwig-Maximilians-University; Roche; Samsung Medical Center; Sanofi; University of Chicago
- Class Antineoplastics; Carbamates; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Colorectal cancer; Gastric cancer
- Registered Pancreatic cancer; Rectal cancer
- Phase II Glioma; Intestinal cancer; Oesophageal cancer
- No development reported Cervical cancer
- Discontinued Biliary cancer; Lung cancer; Nasopharyngeal cancer
Most Recent Events
- 28 Jun 2023 Efficacy data from a phase III trial in Colorectal Cancer presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
- 27 Apr 2023 Chugai Pharmaceuticals submits company opinion for capecitabine for Neuroendocrine tumors to MHLW review comittee (Chugai Pharmaceuticals pipeline, May 2023)
- 24 Jan 2023 CHEPLAPHARM acquires capecitabin (Xeloda®) from Roche